Torray Investment Partners LLC Buys 353 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Torray Investment Partners LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% in the 4th quarter, HoldingsChannel reports. The firm owned 55,611 shares of the biopharmaceutical company’s stock after purchasing an additional 353 shares during the quarter. Torray Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $2,659,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after purchasing an additional 200 shares during the last quarter. Verdence Capital Advisors LLC raised its position in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares during the last quarter. State of New Jersey Common Pension Fund D raised its position in Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after purchasing an additional 302 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 over the last three months. Company insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HALO shares. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright lifted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Down 2.0 %

Shares of Halozyme Therapeutics stock opened at $57.96 on Tuesday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $65.53. The business has a fifty day simple moving average of $54.53 and a 200 day simple moving average of $54.72. The stock has a market cap of $7.14 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.